康寧傑瑞製藥-B(09966.HK)11月25日授出111.34萬股獎勵股份
格隆匯11月25日丨康寧傑瑞製藥-B(09966.HK)宣佈,於2021年11月25日,在取得獎勵股份的上市批准後,公司已根據限制性股份獎勵計劃向12名選定參與者授出合共111.34萬股股份。承授人均為公司僱員且均非公司的關連人士。
已授出的獎勵股份(於公吿日期約佔公司已發行股本的0.1190%及於配發後約佔經擴大已發行股本的0.1188%)將根據公司於2021年6月11日舉行的股東周年大會上由公司股東授予董事的一般授權以配發及發行每股面值0.000002美元的新股份支付。
該等獎勵股份將根據與限制性股份獎勵計劃有關的信託條款發行及配發予Alphamab OEH LTD(("限制性股份單位代名人"),一家於英屬維爾京羣島註冊成立的公司,由受託人達盟信託服務(香港)有限公司持有),並將由受託人以信託方式為受益人的利益間接持有。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.